Eli Lilly has announced a major investment of $5.3 billion in its manufacturing site in Lebanon, Indiana, bringing the total investment to $9 billion.

This operation is designed to boost production capacity for active pharmaceutical ingredients (APIs) for Zepbound (tirzepatide) and Mounjaro (tirzepatide), offering greater capacity for treatments against obesity and type 2 diabetes.

The company has invested more than $16 billion since 2020 in new manufacturing facilities in the United States and Europe.


Copyright (c) 2024 CercleFinance.com. All rights reserved.